company background image
EGRX

Eagle Pharmaceuticals NasdaqGM:EGRX Stock Report

Last Price

US$35.48

Market Cap

US$461.8m

7D

-2.9%

1Y

-27.0%

Updated

01 Dec, 2022

Data

Company Financials +
EGRX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

EGRX Stock Overview

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

Eagle Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eagle Pharmaceuticals
Historical stock prices
Current Share PriceUS$35.48
52 Week HighUS$56.43
52 Week LowUS$24.35
Beta0.80
1 Month Change8.11%
3 Month Change10.05%
1 Year Change-27.00%
3 Year Change-35.99%
5 Year Change-38.32%
Change since IPO176.54%

Recent News & Updates

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Recent updates

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Dec 16
Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Jul 06
Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Apr 15
Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

Mar 25
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

What Type Of Returns Would Eagle Pharmaceuticals'(NASDAQ:EGRX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 07
What Type Of Returns Would Eagle Pharmaceuticals'(NASDAQ:EGRX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Eagle Pharmaceuticals (NASDAQ:EGRX) Has A Pretty Healthy Balance Sheet

Jan 11
Eagle Pharmaceuticals (NASDAQ:EGRX) Has A Pretty Healthy Balance Sheet

Here's Why We Think Eagle Pharmaceuticals's (NASDAQ:EGRX) Statutory Earnings Might Be Conservative

Dec 16
Here's Why We Think Eagle Pharmaceuticals's (NASDAQ:EGRX) Statutory Earnings Might Be Conservative

How Much Is Eagle Pharmaceuticals' (NASDAQ:EGRX) CEO Getting Paid?

Nov 25
How Much Is Eagle Pharmaceuticals' (NASDAQ:EGRX) CEO Getting Paid?

Shareholder Returns

EGRXUS BiotechsUS Market
7D-2.9%2.7%1.4%
1Y-27.0%-10.3%-16.1%

Return vs Industry: EGRX underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: EGRX underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is EGRX's price volatile compared to industry and market?
EGRX volatility
EGRX Average Weekly Movement10.3%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: EGRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: EGRX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007114Scott Tarriffhttps://www.eagleus.com

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.

Eagle Pharmaceuticals, Inc. Fundamentals Summary

How do Eagle Pharmaceuticals's earnings and revenue compare to its market cap?
EGRX fundamental statistics
Market CapUS$461.80m
Earnings (TTM)US$21.28m
Revenue (TTM)US$298.23m

21.7x

P/E Ratio

1.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EGRX income statement (TTM)
RevenueUS$298.23m
Cost of RevenueUS$87.38m
Gross ProfitUS$210.85m
Other ExpensesUS$189.57m
EarningsUS$21.28m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.64
Gross Margin70.70%
Net Profit Margin7.14%
Debt/Equity Ratio26.5%

How did EGRX perform over the long term?

See historical performance and comparison